Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study

van de Hei, Susanne; McKinstry, Steven; Bardsley, George; Weatherall, Mark; Beasley, Richard; Fingleton, James

and was found in one third of participants. There was no evidence of an interaction between the 50 treatment difference in modified Jackson scores for those that were Nasal swab positive or 51 negative. 52 The mean total use of the myAIRVO 2 device was 9.9 hours, a mean (SD) of 2.0 (0.85) hours per 57 day. Eight participants (40%) did not use the myAIRVO 2 device on day 5 and seven participants 58 (35%) used it for less than 4 days. On the days the myAIRVO 2 was used, the mean (SD) use 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 This study has shown that an RCT of rhinothermy via high flow nasal cannulae in the treatment 81 of the common cold is feasible. The study fully recruited 30 participants within an eight week 82 period and all completed the study. Adherence to rhinothermy treatment was good while 83 participants were symptomatic. Although not a primary outcome for the study rhinothermy with 84 the modified myAIRVO 2 device was associated with clinically significant reductions in common 85 cold symptoms compared to treatment with vitamin C. 86 87 This is the first study to investigate rhinothermy using the modified myAIRVO 2 device and 88 strengths include the randomised controlled design and the complete follow-up of all participants. 89